Maculopapular drug eruption induced by linagliptin

Zheng, Miao; Yoshimoto, Norihiro; Muramatsu, Ken; Ito, Takamasa; Ujiie, Hideyuki; Shimizu, Hiroshi

doi:10.1111/ajd.12818

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five cases of exanthematous drug eruption (EDE) have been reported in the literature, it was observed with alogliptin, sitagliptin, linagliptin, teneligliptin, and vildagliptin, time intervals varied from a few hours for teneligliptin to 6 months in sitagliptin, and mean and median healing time after drug withdrawal was 28 and 22 days respectively. The most common comorbidities associated with EDE were hypertension, obesity, and renal impairment, and the most common concomitant medication was metformin [ 14 , 16 , 20 , 24 , 26 ].…”

Section: Fixed Drug Eruptionsmentioning

confidence: 99%

“… Ankur Guliani,2019 [ 19 ] Eczematoid dermatitis Vildagliptin 54 /F – Metformin Voglibose 2 m 1 m 5. Miao Zheng,2018 [ 20 ] Exanthematous drug eruption Linagliptin 41/F Behcet disease Prednisolone, Infliximab 2 m 1 m 6. Elena Succurro,2017 [ 21 ] Loss of eyebrows and eyelashes Sitagliptin 69/M – Metformin 4 m 3 m 7.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review

Zaresharifi,

Niroomand,

Borran

et al. 2024

Clin Diabetes Endocrinol

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs that enhance the incretin-insulin pathway and offer effective glycemic control in type 2 diabetes mellitus. However, these drugs may be associated with various dermatological side effects, ranging from mild to severe. This review article summarizes the current literature on the dermatological side effects of DPP-4 inhibitors, including bullous pemphigoid, severe cutaneous adverse drug reactions, fixed drug eruptions, and other mucocutaneous reactions. The review also discusses the possible mechanisms, risk factors, diagnosis, and management of these side effects. This review aims to increase the awareness and vigilance of healthcare providers in recognizing and managing the dermatological side effects of DPP-4 inhibitors and to emphasize the need for further research and surveillance to optimize diabetes care and patient safety.

show abstract